
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) **November 2, 2011**

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

(Commission File Number)

22-0760120

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

(Address of Principal Executive Offices)

07417-1880

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On November 2, 2011, Becton, Dickinson and Company ("BD") issued a press release announcing its financial results for its fourth fiscal quarter and fiscal year ending September 30, 2011. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles ("non-GAAP measures"), as follows:

- Revenues. We present international and total revenue growth rates (for the total company and each of its segments and units, and for our safety-engineered devices) after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that these measures of revenue growth allow investors to better understand the underlying operating results of BD and facilitate comparisons to prior periods.
- Earnings Per Share from Continuing Operations. We present our diluted earnings per share from continuing operations ("EPS") for the fourth quarter of fiscal year 2011 and for the full 2011 fiscal year after eliminating the non-cash charge resulting from the discontinuance of a research program within our Diagnostic Systems unit. We believe this measure of EPS, adjusted for the impact of this cost, allows investors to more easily compare BD's financial performance with prior periods.

We also present our EPS growth for the fourth quarter of fiscal year 2011 and for the full 2011 fiscal year after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD and facilitates comparisons to prior periods.

We also present our EPS for fiscal year 2010 after eliminating the non-cash charge related to health care reform impacting Medicare Part D reimbursements. This item is not considered by management to be part of ordinary operations. We believe this adjusted measure of EPS is more indicative of BD's underlying performance for fiscal year 2010, and allows investors to better assess our EPS performance for fiscal year 2011.

BD's management uses each of these non-GAAP measures in its own evaluation of BD's performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD's financial results. Management believes the non-GAAP results provide a reasonable measure of BD's underlying performance before the effects of items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD's results.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 Press release dated November 2, 2011, which is furnished pursuant to Item 2.02

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Gary DcFazio
Gary DcFazio
Vice President and Corporate Secretary

Date: November 2, 2011

Exhibit Index

99.1 Press release dated November 2, 2011, which is furnished pursuant to Item 2.02

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com

News Release



Contact:

Monique N. Dolecki, Investor Relations — 201-847-5453
Colleen T. White, Corporate Communications — 201-847-5369

BD ANNOUNCES RESULTS FOR 2011 FOURTH FISCAL QUARTER AND FULL YEAR

Franklin Lakes, NJ (November 2, 2011)— BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of \$2.051 billion for the fourth fiscal quarter ended September 30, 2011, representing an increase of 9.5 percent from the prior-year period, or 4.0 percent on a foreign currency-neutral basis.

For the full fiscal year ended September 30, 2011, BD reported revenues of \$7.829 billion, representing an increase of 6.2 percent over the prior year. On a foreign currency-neutral basis, revenues increased 2.9 percent, despite an unfavorable comparison to the prior year of about 2.0 percentage points due to strong sales related to the H1N1 flu pandemic, supplemental spending in Japan and stimulus spending in the U.S. in fiscal year 2010.

“We are pleased with our solid finish to fiscal year 2011. Despite a challenging business environment, all segments contributed to our success and growth,” said Vincent A. Forlenza, Chief Executive Officer and President. “We will continue to drive operational efficiencies and make capital and R&D investments to support our innovation strategy as we look to fiscal year 2012 and beyond.”

Update on the Acquisition of Carmel Pharma, AB

As announced in August 2011, the Company completed the acquisition of Carmel Pharma, AB, a Swedish company that manufactures the BD PhaSeal™ System. This is the leading closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials. The financial impact of the acquisition on our fourth quarter results was in line with our guidance.

Fourth Quarter Earnings and Analysis of the Full Fiscal Year 2011 and 2010 Earnings

Reported diluted earnings per share from continuing operations for the fourth quarter were \$1.36, compared with \$1.24 in the prior-year period, representing a 9.7 percent increase. Current quarter results included a non-cash charge of \$9 million, or \$0.03 per share from continuing operations, resulting from the discontinuance of a research program within the Diagnostic Systems unit. Excluding this item, adjusted diluted earnings per share from continuing operations increased by 12.1 percent to \$1.39, compared with \$1.24 in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fourth quarter increased by 8.1 percent.

For the full fiscal year ended September 30, 2011, reported diluted earnings per share from continuing operations were \$5.59, compared with \$4.90 in the prior fiscal year, representing an increase of 14.1

percent. Excluding the aforementioned charge of \$9 million, or \$0.03 per share from continuing operations, and the 2010 fiscal year charge of \$0.04 per share from continuing operations related to healthcare reform impacting Medicare Part D reimbursements, adjusted diluted earnings per share from continuing operations increased by 13.8 percent to \$5.62, compared with \$4.94 in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fiscal year increased 8.1 percent.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$1.055 billion, representing an increase of 10.0 percent compared with the prior-year period. Revenues increased 3.8 percent on a foreign currency-neutral basis. Segment revenue growth reflected strong Diabetes Care and international safety sales, along with solid sales of Pharmaceutical Systems products. For the twelve-month period ended September 30, 2011, BD Medical revenues increased 5.6 percent, or 2.3 percent on a foreign currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$642 million, representing an increase of 8.6 percent compared with the prior-year period, or 3.8 percent on a foreign currency-neutral basis. Revenues reflected solid growth in both the Women's Health and Cancer and the Infectious Disease product offerings within the Diagnostic Systems unit. For the twelve-month period ended September 30, 2011, BD Diagnostics revenues increased 7.0 percent, or 3.9 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were \$354 million, representing an increase of 9.6 percent compared with the prior-year period. Revenues increased 4.7 percent on a foreign currency-neutral basis, primarily driven by instrument and reagent sales in the Cell Analysis unit. For the twelve-month period ended September 30, 2011, BD Biosciences revenues increased 6.7 percent, or 3.2 percent on a foreign currency-neutral basis.

Geographic Results

Fourth quarter revenues in the U.S. were \$843 million, representing an increase of 1.3 percent compared with the prior-year period. Revenues outside of the U.S. were \$1.208 billion, representing an increase of 16.0 percent compared with the prior-year period, or 6.1 percent on a foreign currency-neutral basis. International revenue growth was driven by continued strength in safety sales and strong growth in emerging markets. For the twelve-month period ended September 30, 2011, revenues in the U.S. were \$3.356 billion, representing an increase of 2.1 percent compared with the prior-year period. Revenues outside of the U.S. were \$4.473 billion, representing an increase of 9.5 percent compared with the prior-year period, or 3.6 percent on a foreign currency-neutral basis.

Fiscal 2012 Outlook for Full Year

The Company estimates that reported revenues for the full fiscal year 2012 will increase about 1 to 3 percent, or 2 to 4 percent on a foreign currency-neutral basis. Our guidance reflects the anticipated effects of lower healthcare utilization, reduced research funding and global macroeconomic conditions. The Company expects reported diluted earnings per share from continuing operations for fiscal year 2012 to be between \$5.75 and \$5.85. The Company also plans to repurchase, subject to

market conditions, \$1.5 billion of its common stock in fiscal year 2012, and fund the repurchases through ongoing cash flow and the issuance of debt.

Conference Call Information

A conference call regarding BD's fourth quarter results and its expectations for the full fiscal year 2012 will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Wednesday, November 2, 2011. The slides will be available concurrent with the issuance of this press release at www.bd.com/investors. The conference call will be available for replay on BD's website, www.bd.com/investors, or at 855-859-2056 (domestic) and 404-537-3406 (international) through the close of business on Wednesday, November 9, 2011, access code 16826583.

Non-GAAP Financial Measures

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2012 Outlook", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; our ability to successfully integrate any businesses we acquire; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

	Three Months Ended September 30,		
	2011	2010	% Change
REVENUES	\$ 2,050,795	\$ 1,873,195	9.5
Cost of products sold	999,352	900,933	10.9
Selling and administrative	487,232	438,139	11.2
Research and development	126,054	123,606	2.0
TOTAL OPERATING COSTS AND EXPENSES	1,612,638	1,462,678	10.3
OPERATING INCOME	438,157	410,517	6.7
Interest income	1,915	14,594	(86.9)
Interest expense	(22,334)	(12,278)	81.9
Other income, net	1,272	1,285	(1.0)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	419,010	414,118	1.2
Income tax provision	117,606	121,065	(2.9)
INCOME FROM CONTINUING OPERATIONS	301,404	293,053	2.8
(LOSS) INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$81 AND \$27,645, RESPECTIVELY	(1,424)	103,642	NM
NET INCOME	\$ 299,980	\$ 396,695	(24.4)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.39	\$ 1.27	9.4
(Loss) Income from discontinued operations	\$ (0.01)	\$ 0.45	NM
Net income (1)	\$ 1.38	\$ 1.71	(19.3)
Diluted:			
Income from continuing operations	\$ 1.36	\$ 1.24	9.7
(Loss) Income from discontinued operations	\$ (0.01)	\$ 0.44	NM
Net income (1)	\$ 1.36	\$ 1.68	(19.0)
AVERAGE SHARES OUTSTANDING			
Basic	216,726	231,396	
Diluted	220,859	236,316	

NM — Not Meaningful

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

	Twelve Months Ended September 30,		
	2011	2010	% Change
REVENUES	\$ 7,828,904	\$ 7,372,333	6.2
Cost of products sold	3,737,352	3,543,183	5.5
Selling and administrative	1,851,774	1,721,356	7.6
Research and development	476,496	430,997	10.6
TOTAL OPERATING COSTS AND EXPENSES	6,065,622	5,695,536	6.5
OPERATING INCOME	1,763,282	1,676,797	5.2
Interest income	43,209	35,129	23.0
Interest expense	(84,019)	(51,263)	63.9
Other (expense) income, net	(6,209)	497	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	1,716,263	1,661,160	3.3
Income tax provision	451,411	484,820	(6.9)
INCOME FROM CONTINUING OPERATIONS	1,264,852	1,176,340	7.5
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$792 AND \$40,703, RESPECTIVELY	6,142	141,270	NM
NET INCOME	\$ 1,270,994	\$ 1,317,610	(3.5)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 5.72	\$ 5.02	13.9
Income from discontinued operations	\$ 0.03	\$ 0.60	(95.0)
Net income	\$ 5.75	\$ 5.62	2.3
Diluted:			
Income from continuing operations	\$ 5.59	\$ 4.90	14.1
Income from discontinued operations	\$ 0.03	\$ 0.59	(94.9)
Net income	\$ 5.62	\$ 5.49	2.4
AVERAGE SHARES OUTSTANDING			
Basic	221,175	234,328	
Diluted	226,280	240,136	

NM — Not Meaningful

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

	Three Months Ended September 30,		% Change
	2011	2010	
BD MEDICAL			
United States	\$ 404,301	\$ 400,231	1.0
International	650,290	558,374	16.5
TOTAL	\$ 1,054,591	\$ 958,605	10.0
BD DIAGNOSTICS			
United States	\$ 313,603	\$ 307,721	1.9
International	328,445	283,743	15.8
TOTAL	\$ 642,048	\$ 591,464	8.6
BD BIOSCIENCES			
United States	\$ 124,619	\$ 124,009	0.5
International	229,537	199,117	15.3
TOTAL	\$ 354,156	\$ 323,126	9.6
TOTAL REVENUES			
United States	\$ 842,523	\$ 831,961	1.3
International	1,208,272	1,041,234	16.0
TOTAL	\$ 2,050,795	\$ 1,873,195	9.5

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

	Twelve Months Ended September 30,		
	2011	2010	% Change
BD MEDICAL			
United States	\$ 1,625,044	\$ 1,596,336	1.8
International	2,382,260	2,200,096	8.3
TOTAL	\$ 4,007,304	\$ 3,796,432	5.6
BD DIAGNOSTICS			
United States	\$ 1,245,872	\$ 1,214,288	2.6
International	1,234,605	1,104,591	11.8
TOTAL	\$ 2,480,477	\$ 2,318,879	7.0
BD BIOSCIENCES			
United States	\$ 484,853	\$ 475,941	1.9
International	856,270	781,081	9.6
TOTAL	\$ 1,341,123	\$ 1,257,022	6.7
TOTAL REVENUES			
United States	\$ 3,355,769	\$ 3,286,565	2.1
International	4,473,135	4,085,768	9.5
TOTAL	\$ 7,828,904	\$ 7,372,333	6.2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30,
(Unaudited; Amounts in thousands)

	United States		
	2011	2010	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 246,746	\$ 256,290	(3.7)
Diabetes Care	104,819	98,633	6.3
Pharmaceutical Systems	52,736	45,308	16.4
TOTAL	\$ 404,301	\$ 400,231	1.0
BD DIAGNOSTICS			
Preanalytical Systems	\$ 161,556	\$ 162,024	(0.3)
Diagnostic Systems	152,047	145,697	4.4
TOTAL	\$ 313,603	\$ 307,721	1.9
BD BIOSCIENCES			
Cell Analysis	\$ 89,899	\$ 86,765	3.6
Discovery Labware	34,720	37,244	(6.8)
TOTAL	\$ 124,619	\$ 124,009	0.5
TOTAL UNITED STATES	\$ 842,523	\$ 831,961	1.3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

			International		
	2011	2010	Reported	% Change FXN	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 288,653	\$ 245,724	17.5	7.8	9.7
Diabetes Care	119,832	100,468	19.3	7.6	11.7
Pharmaceutical Systems	241,805	212,182	14.0	2.5	11.5
TOTAL	\$ 650,290	\$ 558,374	16.5	5.8	10.7
BD DIAGNOSTICS					
Preanalytical Systems	\$ 167,044	\$ 144,421	15.7	5.7	10.0
Diagnostic Systems	161,401	139,322	15.8	6.2	9.6
TOTAL	\$ 328,445	\$ 283,743	15.8	5.9	9.9
BD BIOSCIENCES					
Cell Analysis	\$ 183,259	\$ 160,230	14.4	6.8	7.6
Discovery Labware	46,278	38,887	19.0	9.5	9.5
TOTAL	\$ 229,537	\$ 199,117	15.3	7.3	8.0
TOTAL INTERNATIONAL	\$ 1,208,272	\$ 1,041,234	16.0	6.1	9.9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

	2011	2010	Total		
			Reported	% Change FXN	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 535,399	\$ 502,014	6.7	1.9	4.8
Diabetes Care	224,651	199,101	12.8	7.0	5.8
Pharmaceutical Systems	294,541	257,490	14.4	4.9	9.5
TOTAL	\$ 1,054,591	\$ 958,605	10.0	3.8	6.2
BD DIAGNOSTICS					
Preanalytical Systems	\$ 328,600	\$ 306,445	7.2	2.5	4.7
Diagnostic Systems	313,448	285,019	10.0	5.2	4.8
TOTAL	\$ 642,048	\$ 591,464	8.6	3.8	4.8
BD BIOSCIENCES					
Cell Analysis	\$ 273,158	\$ 246,995	10.6	5.7	4.9
Discovery Labware	80,998	76,131	6.4	1.6	4.8
TOTAL	\$ 354,156	\$ 323,126	9.6	4.7	4.9
TOTAL REVENUES	\$ 2,050,795	\$ 1,873,195	9.5	4.0	5.5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)

	United States		
	2011	2010	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 980,326	\$ 1,007,322	(2.7)
Diabetes Care	400,809	383,783	4.4
Pharmaceutical Systems	243,909	205,231	18.8
TOTAL	\$ 1,625,044	\$ 1,596,336	1.8
BD DIAGNOSTICS			
Preanalytical Systems	\$ 643,180	\$ 627,421	2.5
Diagnostic Systems	602,692	586,867	2.7
TOTAL	\$ 1,245,872	\$ 1,214,288	2.6
BD BIOSCIENCES			
Cell Analysis	\$ 342,322	\$ 326,916	4.7
Discovery Labware	142,531	149,025	(4.4)
TOTAL	\$ 484,853	\$ 475,941	1.9
TOTAL UNITED STATES	\$ 3,355,769	\$ 3,286,565	2.1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

	International				
	2011	2010	Reported	% Change FXN	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 1,101,407	\$ 1,002,687	9.8	3.5	6.3
Diabetes Care	465,668	401,976	15.8	9.1	6.7
Pharmaceutical Systems	815,185	795,433	2.5	(1.9)	4.4
TOTAL	\$ 2,382,260	\$ 2,200,096	8.3	2.6	5.7
BD DIAGNOSTICS					
Preanalytical Systems	\$ 634,613	\$ 570,386	11.3	4.9	6.4
Diagnostic Systems	599,992	534,205	12.3	5.8	6.5
TOTAL	\$ 1,234,605	\$ 1,104,591	11.8	5.4	6.4
BD BIOSCIENCES					
Cell Analysis	\$ 682,123	\$ 624,322	9.3	4.0	5.3
Discovery Labware	174,147	156,759	11.1	4.1	7.0
TOTAL	\$ 856,270	\$ 781,081	9.6	4.0	5.6
TOTAL INTERNATIONAL	\$ 4,473,135	\$ 4,085,768	9.5	3.6	5.9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

	2011	2010	Total		
			Reported	% Change FXN	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 2,081,733	\$ 2,010,009	3.6	0.4	3.2
Diabetes Care	866,477	785,759	10.3	6.8	3.5
Pharmaceutical Systems	1,059,094	1,000,664	5.8	2.4	3.4
TOTAL	\$ 4,007,304	\$ 3,796,432	5.6	2.3	3.3
BD DIAGNOSTICS					
Preanalytical Systems	\$ 1,277,793	\$ 1,197,807	6.7	3.7	3.0
Diagnostic Systems	1,202,684	1,121,072	7.3	4.2	3.1
TOTAL	\$ 2,480,477	\$ 2,318,879	7.0	3.9	3.1
BD BIOSCIENCES					
Cell Analysis	\$ 1,024,445	\$ 951,238	7.7	4.3	3.4
Discovery Labware	316,678	305,784	3.6	—	3.6
TOTAL	\$ 1,341,123	\$ 1,257,022	6.7	3.2	3.5
TOTAL REVENUES	\$ 7,828,904	\$ 7,372,333	6.2	2.9	3.3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
SAFETY REVENUES
(Unaudited; Amounts in thousands)

	Three Months Ended September 30,				
	2011	2010	% Change		
			Reported	FXN	FX Impact
TOTAL SAFETY REVENUES					
United States	\$ 288,541	\$ 282,968	2.0	2.0	—
International	209,209	160,396	30.4	18.5	11.9
TOTAL	\$ 497,750	\$ 443,364	12.3	7.9	4.4
BY SEGMENT					
BD Medical	\$ 243,521	\$ 208,822	16.6	12.4	4.2
BD Diagnostics	254,229	234,542	8.4	4.0	4.4
TOTAL	\$ 497,750	\$ 443,364	12.3	7.9	4.4
	Twelve Months Ended September 30,				
	2011	2010	% Change		
			Reported	FXN	FX Impact
TOTAL SAFETY REVENUES					
United States	\$ 1,116,543	\$ 1,108,431	0.7	0.7	—
International	754,739	621,913	21.4	13.6	7.8
TOTAL	\$ 1,871,282	\$ 1,730,344	8.1	5.4	2.7
BY SEGMENT					
BD Medical	\$ 885,156	\$ 819,084	8.1	5.4	2.7
BD Diagnostics	986,126	911,260	8.2	5.3	2.9
TOTAL	\$ 1,871,282	\$ 1,730,344	8.1	5.4	2.7

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL INFORMATION
 FY2011 Quarter-to-Date Reconciliation
 (Unaudited; Amounts in millions, except per share data)

	Three Months Ended September 30,				
	Reported FY 2011	Impairment Charge (1)	Adjusted FY 2011	Reported FY 2010	Adjusted % Growth
Diluted Earnings per share from Continuing Operations	\$ 1.36	\$ 0.03	\$ 1.39	\$ 1.24	12.1%

(1) Represents a non-cash impairment charge resulting from the discontinuance of a research program within the Diagnostic Systems unit.

All figures rounded. Totals may not add due to rounding.

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL INFORMATION
 FY2011 Year-to-Date Reconciliation
 (Unaudited; Amounts in millions, except per share data)

	Twelve Months Ended September 30,						
	Reported FY 2011	Impairment Charge (1)	Adjusted FY 2011	Reported FY 2010	Tax (2)	Adjusted FY 2010	Adjusted % Growth
Diluted Earnings per Share from Continuing Operations	\$ 5.59	\$ 0.03	\$ 5.62	\$ 4.90	\$ 0.04	\$ 4.94	13.8%

(1) Represents a non-cash impairment charge resulting from the discontinuance of a research program within the Diagnostic Systems unit.

(2) Represents a non-cash charge related to healthcare reform impacting Medicare Part D reimbursements.

All figures rounded. Totals may not add due to rounding.

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL INFORMATION
 Quarter-to-Date Fiscal 2011 Reconciliation — FX Impact
 (Unaudited; Amounts in millions, except per share data)

	Three Months Ended September 30,							
	Adjusted FY 2011	Reported FY 2010	Adjusted Growth \$	Foreign Currency Translation	FY10 Hedge Gain	Total FX	Adjusted FXN Change	FXN Growth
REVENUES	\$ 2,051	\$ 1,873	\$ 178	\$ 115	\$ (11)	\$ 103	\$ 74	4.0%
Diluted Earnings per Share from Continuing Operations	\$ 1.39	\$ 1.24	\$ 0.15	\$ 0.08	\$ (0.03)	\$ 0.05	\$ 0.10	8.1%

All figures rounded. Totals may not add due to rounding.

FXN = Foreign Currency Neutral

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL INFORMATION
 Year-to-Date Fiscal 2011 Reconciliation — FX Impact
 (Unaudited; Amounts in millions, except per share data)

	Twelve Months Ended September 30,							
	Adjusted FY 2011	Adjusted FY 2010	Adjusted Growth \$	Foreign Currency Translation	FY10 Hedge Loss	Total FX	Adjusted FXN Change	FXN Growth
REVENUES	\$ 7,829	\$ 7,372	\$ 457	\$ 208	\$ 31	\$ 240	\$ 217	2.9%
Diluted Earnings per Share from Continuing Operations	\$ 5.62	\$ 4.94	\$ 0.68	\$ 0.20	\$ 0.08	\$ 0.28	\$ 0.40	8.1%

All figures rounded. Totals may not add due to rounding.

FXN = Foreign Currency Neutral